Dynavax Technologies Corporatio (DVAX) Financials
DVAX Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| 2023-12-31 | 997.1 million | 375.0 million |
| 2023-09-30 | 972.9 million | 368.0 million |
| 2023-06-30 | 936.4 million | 359.2 million |
| 2023-03-31 | 969.9 million | 406.2 million |
DVAX Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| 2023-12-31 | 12.0 million | 11.3 million |
| 2023-09-30 | 30.8 million | 10.7 million |
| 2023-06-30 | 27.3 million | 10.6 million |
| 2023-03-31 | 26.3 million | 10.0 million |
DVAX Net Income
No data available :(
DVAX Cash and Debt
Graph available only for supporters. Become a supporter to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| 2023-12-31 | 742.3 million | - | 34.2 million |
| 2023-09-30 | 720.4 million | - | 35.1 million |
| 2023-06-30 | 681.5 million | - | 35.7 million |
| 2023-03-31 | 652.0 million | 221.9 million | 36.0 million |
DVAX Shares Outstanding
DVAX Expenses
Graph available only for supporters. Become a supporter to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| 2023-12-31 | 1.7 million | 14.1 million | 41.3 million | -70.4 million |
| 2023-09-30 | 347000 | 14.1 million | 38.1 million | - |
| 2023-06-30 | 751000 | 13.0 million | 37.1 million | - |
| 2023-03-31 | 1.3 million | 13.6 million | 36.5 million | - |
DVAX Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| 2023-12-31 | 55.6 million | 8.7 million |
| 2023-09-30 | 69.5 million | 13.2 million |
| 2023-06-30 | 60.2 million | 13.5 million |
| 2023-03-31 | 46.9 million | 14.7 million |
DVAX
Price: $11.72
52 week price:
Earnings Per Share: -0.05 USD
P/E Ratio: 30.44
Exchange: NMS
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Volume: 1.5 million
Ebitda: -21.6 millionMarket Capitalization: 1.5 billion